CRISPR Technology for Adenocarcinoma: Treatment of Pancreatic Cancer

Pancreatic cancer is one of the most fatal cancers, with a five-year survival rate of just 7.2% of diagnosed patients. The current treatments available for pancreatic cancer are often unsuccessful, creating a pressing need for more effective therapeutic options. CRISPR gene editing has emerged as a powerful tool with the potential to revolutionize cancer treatment strategies. Experiments using CRISPR in animal models have successfully stopped pancreatic cancer progression. CRISPR-based treatment strategies can work at different levels to control the progression of the disease. This review discusses three approaches that can be used to treat pancreatic cancer using CRISPR technology, which includes gene editing to silence harmful mutations, regulate the release of harmful biochemical factors, and use bacterial species to attack solid tumors. Mutations in 4 genes, namely KrasG12D, TP53, and BRCA 1&2, can be manipulated with the help of CRISPR technology. Controlled release of hypoxia-inducible factor-1α can regulate tumor development, and genetically manipulated bacterial species can directly attack the tumor cells.